Preclinical News and Research

RSS

Dietary restriction boosts antitumour immunity by rewiring T cell metabolism

Dietary restriction reshapes CD8+ T cell metabolism by increasing ketone body–driven acetyl-CoA production, preventing terminal exhaustion and enhancing tumour control in mice. This metabolic reprogramming also boosts responsiveness to PD-1 blockade, suggesting a potential strategy to improve cancer immunotherapy.

10 Dec 2025

Researchers unravel why mRNA-based vaccines for COVID-19 can cause heart damage

Stanford Medicine investigators have unearthed the biological process by which mRNA-based vaccines for COVID-19 can cause heart damage in some young men and adolescents - and they've shown a possible route to reducing its likelihood.

10 Dec 2025

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

WSU researchers discover how a neural circuit drives relapse after opioid use

Washington State University researchers have discovered how a neural circuit – or a connection between two brain regions – drives relapse after opioid use, a finding that could lead to more effective treatments for opioid use disorders.

9 Dec 2025

Study uncovers how the body's bile acids bind to block C. diff's most dangerous toxin

In a major step towards a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to block C. diff's most dangerous toxin.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The Journal of Cystic Fibrsosis.

9 Dec 2025

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Early-life RSV infection and parental allergy interact to substantially increase childhood asthma risk, supported by population data from more than 1.5 million children and mechanistic mouse experiments. The study shows that viral infection reprograms neonatal immune responses by altering how maternally transferred allergen-specific antibodies are handled, driving long-term allergic airway disease.

8 Dec 2025

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high rates of death unrelated to cancer relapse-primarily infection-and may be avoidable.

8 Dec 2025

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast cancers treatable with targeted therapies.

5 Dec 2025

First new fibromyalgia drug in 15 years, Tonmya (cyclobenzaprine HCl) gains FDA approval and hits pharmacy shelves

In a milestone moment for chronic pain management, Tonix Pharmaceuticals announced on August 15, 2025, that its novel sublingual therapy Tonmya has received approval from the U.S. Food and Drug Administration (FDA) - marking the first new drug for Fibromyalgia in more than 15 years.

From Hanson Wade Group - Non-Opioid Pain Therapeutics Summit 5 Dec 2025

Ripple & Bausch’s licensing agreement: What it means in ocular delivery

Ripple Therapeutics, a clinical-stage company developing polymer-free sustained release drug delivery systems, has entered into an evaluation and licensing option agreement with an affiliate of Bausch + Lomb.

From Hanson Wade Group - 4th Ophthalmic Drug Delivery Summit 5 Dec 2025

Engineered herpes virus activates potent immune responses against glioblastoma

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

4 Dec 2025

Study shows glial cells actively shape addictive responses to nicotine

Nicotine addiction remains one of the most persistent public health challenges worldwide, driven by changes in the brain that reinforce repeated use and make quitting extremely difficult.

4 Dec 2025

Study uncovers strategy to sensitize estrogen receptor–positive breast tumors to immunotherapy

A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common tumor type, estrogen receptor-positive or luminal breast cancer.

4 Dec 2025

Organ-on-a-chip system reveals how aging weakens vaccine-driven anti-cancer immunity

Dr. Vadim Jucaud's lab at the Terasaki Institute has introduced a new organ-on-a-chip platform that recapitulates age-dependent immune responses, offering a more accurate testing bed for evaluating cancer vaccine performance in older adults, the population most affected by cancer and often overlooked in traditional preclinical testing.

4 Dec 2025

Common water pill may be a useful add‑on to the standard HIV treatment

An FDA‑approved medication called spironolactone, often prescribed as a diuretic, or water pill, for heart and blood pressure conditions, may be a useful add‑on to the standard HIV treatment, according to new research from the Valente lab at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology.

2 Dec 2025

Generative AI aids discovery of ISM3830's novel scaffold

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and master negative regulator of T‑cell and natural killer (NK) cell activation, playing a central role in modulating T-cell activation and immune tolerance, and its inhibition enhances T cells and NK cells function, also provides a strategy for the function restoration of exhausted T cells.

1 Dec 2025

Circadian rhythms can influence outcomes related to influenza infections

Researchers at Children's Hospital of Philadelphia (CHOP) found that circadian rhythms – the biological clocks of the body – can influence outcomes related to influenza infections, providing clinicians with insight about how biological processes can be used to optimize care for critically ill patients with respiratory viral infections.

1 Dec 2025

New consortium aims to fast-track breakthroughs against follicular lymphoma

Follicular lymphoma (FL) is the second most frequent subtype of non-Hodgkin lymphoma, a cancer of the immune system. Although the disease is typically incurable, many cases progress slowly and do not require immediate treatment.

1 Dec 2025

Preclinical News and Research

Dietary restriction boosts antitumour immunity by rewiring T cell metabolism

Researchers unravel why mRNA-based vaccines for COVID-19 can cause heart damage

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

WSU researchers discover how a neural circuit drives relapse after opioid use

Study uncovers how the body's bile acids bind to block C. diff's most dangerous toxin

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

First new fibromyalgia drug in 15 years, Tonmya (cyclobenzaprine HCl) gains FDA approval and hits pharmacy shelves

Ripple & Bausch’s licensing agreement: What it means in ocular delivery

Engineered herpes virus activates potent immune responses against glioblastoma

Study shows glial cells actively shape addictive responses to nicotine

Study uncovers strategy to sensitize estrogen receptor–positive breast tumors to immunotherapy

Organ-on-a-chip system reveals how aging weakens vaccine-driven anti-cancer immunity

Common water pill may be a useful add‑on to the standard HIV treatment

Generative AI aids discovery of ISM3830's novel scaffold

Circadian rhythms can influence outcomes related to influenza infections

New consortium aims to fast-track breakthroughs against follicular lymphoma

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics